Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of the National Cancer Institute|June 11, 2009
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferonMarna G Bouwhuis, Stefan Suciu, Sandra Collette, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trialPatrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2010
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 studyMartin Kocher, Riccardo Soffietti, Ufuk Abacioglu, et al.
European Urology|July 27, 2015
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-GuérinSamantha Cambier, Richard J Sylvester, Laurence Collette, et al.
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
European Urology|March 3, 2023
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell ScoreMatthew D Galsky, Dean F Bajorin, Johannes Alfred Witjes, et al.
The Lancet. Oncology|December 16, 2014
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trialHarry Bartelink, Philippe Maingon, Philip Poortmans, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 23, 2025
Radiotherapy quality assurance of the prospective randomised EORTC-1219/DAHANCA-29 trial: an individual case review analysisNajlaa Alyamani, André Abrunhosa-Branquinho, Coreen Corning, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2008
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'Sandra Collette, Laurence Collette, Tom Budiharto, et al.
JAMA Oncology|December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical TrialAxel Bex, Peter Mulders, Michael Jewett, et al.
Pageof 5